Skip to content
ClinCalc Pro
Menu
Antifungal — ABPA / Chronic Pulmonary Aspergillosis

Itraconazole (Respiratory)

Brand names: Sporanox

A triazole antifungal used in respiratory practice for conditions such as allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis. Absorption varies by formulation, with the oral liquid generally better absorbed than capsules.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Itraconazole.

Clinical monograph

How it works

Itraconazole inhibits fungal cytochrome P450-dependent synthesis of ergosterol, disrupting the fungal cell membrane and inhibiting growth of Aspergillus and other susceptible fungi.

Prescribing in practice

  • It is a potent CYP3A4 inhibitor with extensive, sometimes dangerous drug interactions, so screen co-medication carefully and avoid contraindicated combinations before prescribing.
  • Avoid in ventricular dysfunction or heart failure because itraconazole has negative inotropic effects, and monitor for hepatotoxicity.
  • Capsule absorption depends on gastric acid and food, so acid-suppressing drugs reduce levels and the formulation and administration conditions matter.

Monitoring

Monitor liver function, signs of cardiac failure, and where indicated plasma drug concentrations to confirm adequate exposure during prolonged therapy.

Counselling the patient

  • Tell your team about all other medicines, including over-the-counter ones, because interactions are common.
  • Report ankle swelling, breathlessness or symptoms of liver upset such as nausea or yellowing.

Evidence & guidelines

Itraconazole is an established antifungal for aspergillus-related lung disease per BTS and specialist mycology guidance.

Reference: Stevens et al. NEJM 2000 (itraconazole ABPA); ESCMID/ECMM/ERS Aspergillosis Guidelines 2018; NICE guideline; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.